The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.
Related Keywords
, Jeffrey Weber , Langone Health , Perlmutter Cancer Center , Resected Melanoma , Mrna 4157 , Pembrolizumab , Esmo Congress ,
vimarsana.com © 2020. All Rights Reserved.